Purchase this article with an account.
Kentaro Senba, Tatsuro MIyamoto, Hiroshi Eguchi, Yoshinori Mitamura; The Efficacy Of Oral Pilocarpine For The Treatment Of Dry Eye Symptoms In Patients With Aqueous Tear Deficiency And Evaporative Dry Eye. Invest. Ophthalmol. Vis. Sci. 2011;52(14):3837.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate the efficacy and safety of oral pilocarpine (Salagen® Tab. 5mg) administration to the patients with both aqueous-deficient dry eye and evaporative dry eye.
Nineteen cases of aqueous-deficient dry eye patients and 8 cases of evaporative dry eye patients were randomized to receive 5mg to 15mg oral pilocarpine for 4 weeks. All participants were evaluated at baseline and each visit of week 1, 2, and 4. To assess the efficacy, Shirmer’s-1 test, break up time test (BUT), fluorescein stain score, and questioning about ocular symptoms were obtained. To assess the safety, questioning about systemic side effect was obtained. Student-t test was used as a statistical analysis.
Shirmer’s-1 test value, 8.5±8.4mm at baseline,change to 7.3±4.0mm (p=0.33), 10.1±8.1 (p=0.33), 8.5±6.6 (p=0.97) in week 1, 2, and 4, respectively. BUT, 2.4±1.5sec at baseline, were significantly increased up to 3.6±1.2sec (p<0.01), 4.4±1.8sec (p<0.01), 4.6±2.0sec (p<0.01) in week 1, 2, and 4, respectively. Fluorescein stain score, 3.2±1.9 at baseline, decreased to 2.8±1.9 (p=0.21), 3.0±2.2 (p=0.02), 2.1±1.8 (p<0.01), in week 1, 2, and 4, respectively. Ocular symptoms improved in 15 cases and remained stable in 12 cases. Ocular discomfort improved in 4 of 8 evaporative dry eye cases. Most of systemic side effects were nausea, hyperhidrosis, increase saliva production, and all symptoms were within the allowance of all participants.
Oral pilocarpine is effective in improving the symptoms of patients with both aqueous-deficient dry eye and evaporative dry eye, and is safe for clinical use in Ophthalmology.
Clinical Trial: :
This PDF is available to Subscribers Only